May 17th 2024
A reduced dosing duration of venetoclax plus hypomethylating agents may be appropriate for elderly patients with acute myeloid leukemia.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
HuCART19 Achieved Durable, Robust Responses in Adult and Pediatric R/R B-ALL
July 14th 2021A new study has adapted CAR to look more human to the body, which will then in turn yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
CA-4948 Garners Positive Early Results in Relapsed/Refractory AML and MDS
July 13th 2021The updated results of an ongoing phase 1/2 study indicated that CA-4948 achieved promising responses and a tolerable safety profile in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
Early Efficacy, Safety Noted With Lisaftoclax in First-in-Human CLL Trial
July 7th 2021In a trial of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and other hematologic cancers, the BCL-2 inhibitor lisaftoclax demonstrated feasibility as a treated option in the relapsed or refractory setting.
Combination Therapy With Ibrutinib and Venetoclax Bests Chlorambucil/Obinutuzumab for CLL
June 14th 2021The risk of progression or death was statistically significantly reduced with the use of ibrutinib and venetoclax versus chlorambucil plus obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Zandelisib/Zanubrutinib Combination in R/R CLL and B-Cell Malignancies Shows Clinical Benefit
June 12th 2021Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.
ALPINE Trial Points to Favorability of Zanubrutinib in Relapsed/Refractory CLL/SLL Versus Ibrutinib
June 11th 2021Data from EHA 2021 showed that zanubrutinib was associated with better outcomes over ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Paul M. Barr, MD, Examines Head-to-Head Data on BTK Inhibitors in Previously Treated, High-Risk CLL
June 9th 2021CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about what data has the greatest potential to impact standard treatment of chronic lymphocytic leukemia.
Survival Benefit at 7 Years Reported With First-Line Ibrutinib for Chronic Lymphocytic Leukemia
June 5th 2021Median progression-free and overall survival in patients with CLL/SLL receiving ibrutinib in the frontline still not reached at 7-year follow-up, according to data from RESONATE-2 trial reported at the 2021 ASCO Annual Meeting.
Paul M. Barr, MD, Discussed 7-Year Follow-Up Data for Ibrutinib as Frontline Treatment of CLL
June 4th 2021CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about data from RESONATE-2 showing sustained progression-free and overall survival in patients with chronic lymphocytic leukemia being treated with ibrutinib in the frontline setting.